News tagged with proteasome inhibitor
Immunoproteasome crystal structure determined
Like a shredder, the immunoproteasome cuts down proteins into peptides that are subsequently presented on the cellular surface. The immune system can distinguish between self and nonself peptides and selectively ...
Feb 16, 2012 |
not rated yet |
0
Researchers identify potential new drug for neurodegenerative disease
Scientists have discovered a small molecule that helps human cells get rid of the misfolded, disfigured proteins implicated in Alzheimer's disease and other neurodegenerative ailments. This potential drug could have applications ...
Medicine & Health / Medical research
Sep 08, 2010 |
5 / 5 (3) |
0
|
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
(PhysOrg.com) -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today ...
Nov 05, 2009 |
not rated yet |
0
Search results for proteasome inhibitor
Scientists identify major source of cells' defense against oxidative stress
Both radiation and many forms of chemotherapy try to kill tumors by causing oxidative stress in cancer cells. New research from USC on a protein that protects cancer and other cells from these stresses could one day help ...
Apr 06, 2012 |
4.5 / 5 (4) |
0
|
New class of drugs for the reversible inhibition of proteasomes
As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they ...
Nov 22, 2011 |
not rated yet |
0
A new mechanism for reversible proteasome inhibition
In their function as cellular recycling plants, proteasomes fulfill a life-sustaining role in all cells -- including cancer cells. When the proteasomes become inhibited, cells suffocate in their own waste. ...
Dec 13, 2010 |
5 / 5 (1) |
0
Drug combination shows promise for newly diagnosed blood cancer patients, study finds
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer ...
Dec 09, 2010 |
not rated yet |
0
Study finds bortezomib to be promising treatment for rheumatoid arthritis
A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis ...
Medicine & Health / Diseases, Conditions, Syndromes
Nov 03, 2010 |
5 / 5 (1) |
0
Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE), the first in a new class of cancer drugs known as proteasome inhibitors, works ...
Jul 12, 2010 |
5 / 5 (2) |
0
'Vicious circle' offers new acute leukemia treatment target
Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.
Apr 13, 2010 |
not rated yet |
0
Researchers find new method of fixing broken proteins to treat genetic diseases
Researchers at Fox Chase Cancer Center have demonstrated how it could be possible to treat genetic diseases by enhancing the natural ability of cells to restore their own mutant proteins. In particular, they found that drugs ...
Jan 15, 2010 |
4.7 / 5 (3) |
0
IKK may act as both inhibitor and promoter of Huntington's disease
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, ...
Dec 21, 2009 |
not rated yet |
0
Drug shows positive responses, low side-effects in multiple myeloma
NEW ORLEANS ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers ...
Dec 07, 2009 |
not rated yet |
0
List of search results for proteasome inhibitor
